Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

NSAIDs: The Heart of the Controversy

Kurt Ullman  |  Issue: June 2007  |  June 1, 2007

As with most other medications, NSAIDs are not something that can be prescribed and then forgotten about. Frequent follow-up with the patient to assess changes in blood pressure, swelling of the extremities, and possible gastrointestinal problems needs to be accomplished. Instructing the patient to recognize these side effects and report them immediately to their physician is also important.

It is important to review with your patients the reasons you think the prescribed medication is the best choice. The controversy over NSAID safety—especially that of COX-2 inhibitors—has changed the dynamic between the doctor and the patient.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Before the concerns were raised, most of my patients wanted something that would ease their pain,” said Dr. Borenstein. “Their sensitivity level is such that safety now is a greater concern than efficacy in regard to their problem. This idea of having a safe medication and then seeing if it works is putting the cart before the horse.”

Careful patient education is one way to alleviate patients’ safety concerns. “What I try to do when I give any drug is talk about what kinds of side effects they can expect,” says Leslie J. Crofford, MD, chief of the division of rheumatology at the University of Kentucky College of Medicine in Lexington. “For non-specific and COX-2–specific inhibitors, I mention that there might be a small increase in incidence of heart attacks. I also mention that the risk for gastrointestinal bleeding and other adverse events for some of these medications is much higher than the risk for heart attack depending on individual comorbidities. If they remain uncomfortable with a particular drug, you have to respect their wishes.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, the rheumatologist has to weigh the desirable and undesirable effects of the medication and decide what is best for that particular patient, according to those interviewed.

Rheumatologists recommend these sites for reliable patient-education materials:

ACR NSAIDs patient education fact sheet:
www.rheumatology.org/public/factsheets/nsaids.asp

Arthritis Today NSAIDs drug guide:
www.arthritis.org/arthritistoday/drugguide/about_nsaids.asp

Concerns with the Science

One of the concerns expressed by rheumatologists interviewed here is that the Circulation article takes a “tunnel view” of the situation by focusing on cardiovascular effects without weighing other concerns. For example, the use of narcotic analgesics raises concerns of its own, including constipation, dizziness, and falls in older patients.

Others question the science behind the AHA Statement. “There are two areas of misrepresentation that I see,” says Dr. Abramson. “There is no evidence, with the exception of high-dose naproxyn in a clinical-trial setting, that COX-2–specific inhibitors carry a greater cardiovascular risk than traditional NSAIDs, yet their algorithm suggests that they are safer than COX-2 inhibitors. They also suggest starting treatment with ASA, non-ASA, and opioids which is totally outrageous because there is no data to support it.”

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:AnalgesicsDrug Updates Tagged with:AC&RdosageNonsteroidal anti-inflammatory drugs (NSAIDs)patient carerheumatologistSafetyside effect

Related Articles
    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    The Why & What of the ACR's Clinical Practice Guidelines

    The Why & What of the ACR’s Clinical Practice Guidelines

    February 18, 2018

    With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

    Why Tweaking Molecular Structures Can Be Hazardous to Our Health

    June 1, 2014

    The rise and fall of rofecoxib and valdecoxib demonstrate the need for caution in new drug development

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences